1-20 of 144
Craig C Hofmeister
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise
Journal: Blood
Blood (2023) 142 (Supplement 1): 4699.
https://doi.org/10.1182/blood-2023-181783
Published: 2023
Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov
Journal: Blood
Blood (2023) 142 (Supplement 1): 4974.
https://doi.org/10.1182/blood-2023-191148
Published: 2023
Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial
Journal: Blood
Blood (2023) 142 (Supplement 1): 4764.
https://doi.org/10.1182/blood-2023-190871
Published: 2023
Journal Articles

Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter M. Voorhees, Irwindeep Sandhu, Matthew W. Jenner, Dean Smith, Michele Cavo, Niels WCJ van de Donk, Meral Beksac, Philippe Moreau, Hartmut Goldschmidt, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, Craig C. Hofmeister
Journal: Blood
Blood (2023) 142 (Supplement 1): 210.
https://doi.org/10.1182/blood-2023-181765
Published: 2023
Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar
Journal: Blood
Blood (2023) 142 (Supplement 1): 3387.
https://doi.org/10.1182/blood-2023-184949
Published: 2023
Journal Articles

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Ellen Marin, Sara Scott, Kathryn Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
Journal: Blood
Blood (2023) 142 (Supplement 1): 2008.
https://doi.org/10.1182/blood-2023-189878
Published: 2023
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Noffar Bar, Maria Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig C. Hofmeister, Paula Rodriguez Otero, Maria Aranzazu Bermúdez, Thomas Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier De La Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian Kiesel, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Costa
Journal: Blood
Blood (2023) 142 (Supplement 1): 2011.
https://doi.org/10.1182/blood-2023-180013
Published: 2023
Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

Paul G. Richardson, Irwindeep Sandhu, Craig C. Hofmeister, Robert Z. Orlowski, Darrell White, Angelo Belotti, Charlotte Toftmann Hansen, Noopur S. Raje, Tracy T. Chow, Zehua Zhou, Tiziana Civardi, Phillip Koo, Yue Zhu, Jessica Katz, Albert Oriol
Journal: Blood
Blood (2023) 142 (Supplement 1): 1013.
https://doi.org/10.1182/blood-2023-174443
Published: 2023
Journal Articles

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Carlyn Tan, Neha Korde, Andriy Derkach, Malin Hultcrantz, Kylee H Maclachlan, Hani Hassoun, Sham Mailankody, Urvi A Shah, Sridevi Rajeeve, Dhwani Patel, Alexander Lesokhin, Oscar Boutros Lahoud, Gunjan L. Shah, Michael Scordo, David Chung, Heather Landau, Sergio A. Giralt, Craig C. Hofmeister, Jonathan L. Kaufman, Ajay K. Nooka, Saad Z Usmani, Sagar Lonial, Nisha S. Joseph
Journal: Blood
Blood (2023) 142 (Supplement 1): 1996.
https://doi.org/10.1182/blood-2023-190279
Published: 2023
Journal Articles

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Ana Maria Avila Rodriguez, Danny Hadidi, Craig C. Hofmeister, John Quigley, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, Matias Eugenio Sanchez, Shrihari Kadkol, Douglas Sborov, Damiano Rondelli, Chukwuemeka Uzoka, Karen Sweiss
Journal: Blood
Blood (2023) 142 (Supplement 1): 3395.
https://doi.org/10.1182/blood-2023-190011
Published: 2023
Journal Articles

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Nisha S. Joseph, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka
Journal: Blood
Blood (2023) 142 (Supplement 1): 647.
https://doi.org/10.1182/blood-2023-187339
Published: 2023
Journal Articles

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

R Donald Harvey, Joseph K Franz, Nisha S. Joseph, Jonathan L. Kaufman, Elise Hitron, Hannah Collins, Catherine Braga, Ludimila Cavalcante, Kathryn T. Maples, Craig C Hofmeister, Madhav Dhodapkar, Sagar Lonial, Ajay K. Nooka
Journal: Blood
Blood (2022) 140 (Supplement 1): 12633–12634.
https://doi.org/10.1182/blood-2022-157047
Published: 2022
Journal Articles

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Jordan Ciuro, Elizabeth Henry, Nadine Housri, Rahul Banerjee, Elizabeth A Brem, Taylor Brooks, Ben A. Derman, Brian T. Hill, Craig C Hofmeister, Matthew A. Lunning, Matthew J. Matasar, Tycel J. Phillips, Sarah C. Rutherford, Saurabh Zanwar, Lauren E Lee
Journal: Blood
Blood (2022) 140 (Supplement 1): 13180–13181.
https://doi.org/10.1182/blood-2022-167959
Published: 2022
Journal Articles

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Jordan M Schecter, Christina Y Sheng, Dawei Song, Xiaoying Xu, Yaming Su, Weirong Wang, Deepu Madduri, Carolyn C Jackson, Enrique Zudaire, Tzu-min Yeh, Tito Roccia, Dong Geng, Lida Pacaud, Douglas W Sborov, Mitch A Phelps, Craig C Hofmeister
Journal: Blood
Blood (2022) 140 (Supplement 1): 4323–4324.
https://doi.org/10.1182/blood-2022-159501
Published: 2022
Journal Articles

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

Laura Sun, Kathryn T. Maples, Kevin H. Hall, Yuan Liu, Yichun Cao, Nisha S. Joseph, Craig C Hofmeister, Jonathan L. Kaufman, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, R Donald Harvey
Journal: Blood
Blood (2022) 140 (Supplement 1): 7131–7132.
https://doi.org/10.1182/blood-2022-159189
Published: 2022
Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho
Journal: Blood
Blood (2022) 140 (Supplement 1): 4434–4435.
https://doi.org/10.1182/blood-2022-163737
Published: 2022
Journal Articles

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Karen Sweiss, Craig C Hofmeister, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, John G. Quigley, Shrihari Kadkol, Douglas W. Sborov, Damiano Rondelli, Pritesh Patel
Journal: Blood
Blood (2022) 140 (Supplement 1): 7304–7305.
https://doi.org/10.1182/blood-2022-170936
Published: 2022
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong, Noffar Bar, Laura Paris, Craig C Hofmeister, Markus Hansson, Armando Santoro, Maria-Victoria Mateos, Paula Rodríguez-Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano J. Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 400–402.
https://doi.org/10.1182/blood-2022-159009
Published: 2022
Journal Articles

Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant

Karen Sweiss, Craig C Hofmeister, John G. Quigley, Jaleel G. Sweis, Kaily Kurzweil, Douglas W. Sborov, Lisa Sharp, Gregory S Calip, Lucas Maahs, Ana Maria Avila, Chukwuemeka Uzoka, Elizabeth Ilo, Elliot Wolf, Damiano Rondelli, Pritesh Patel
Journal: Blood
Blood (2022) 140 (Supplement 1): 5252–5253.
https://doi.org/10.1182/blood-2022-171045
Published: 2022
Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Krina Patel, Nina Shah, Alan Tan, Andrew J Cowan, Cameron J. Turtle, Craig C Hofmeister, Taewoong Choi, Hayder Saeed, Julio C. Chavez, Matthew J. Pianko, Mitul Gandhi, Sohail A. Chaudhry, Zachary Lee, Neha Dixit, Christie Fanton, Xiaoli Wang, Heng Xu, Mario Q. Marcondes, Mary A. Tagliaferri, Jonathan Zalevsky, Miguel-Angel Perales
Journal: Blood
Blood (2022) 140 (Supplement 1): 10357–10359.
https://doi.org/10.1182/blood-2022-162539
Published: 2022